By Turna Ray

As KRAS testing becomes part of standard clinical practice in guiding treatment for colorectal cancer patients, two competing drug companies are racing to look for gene markers beyond KRAS that will allow them to differentiate their EGFR-inhibiting monoclonal antibody therapies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.